Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-14
2009-12-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S412000, C514S064000, C514S075000, C548S405000, C548S412000, C548S416000
Reexamination Certificate
active
07625939
ABSTRACT:
The present invention relates to DP IV-inhibitors of formula (1)for the treatment and/or prophylaxis of diseases of mammals including cancer and tumors, metastasis and tumor colonization; and metabolic diseases.
REFERENCES:
patent: 6303661 (2001-10-01), Demuth
patent: 19828114 (2000-01-01), None
patent: 19828113 (2008-11-01), None
patent: 9529691 (1995-11-01), None
patent: 9740832 (1997-11-01), None
patent: 9938501 (1999-08-01), None
patent: 9961431 (1999-12-01), None
patent: 9967228 (1999-12-01), None
patent: 9967279 (1999-12-01), None
patent: 0119866 (2001-03-01), None
patent: 0168603 (2001-09-01), None
patent: 0204610 (2002-01-01), None
patent: 0231134 (2002-04-01), None
patent: 0234900 (2002-05-01), None
patent: 03002593 (2003-01-01), None
patent: 2005047297 (2005-05-01), None
Stella, Valentino J, Expert Opinion of Therapeutic Patents, Prodrugs as therapeutics, 2004 14(3): 277-280.
Wolff et al. (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977, 1994).
Testa, Bernard, Biochemical Pharmacology, Prodrug Research: futile or fertile? 68 (2004) 2097-2106.
Ettmayer, Peter, Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, 47(10) (2004) 2394-2404.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Design of Prodrugs, Ed. H. Bundgaard, Elsevier, 1985.
Sedo and Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?, Biochimica et Biophysica Acta, 2001, p. 1-10, vol. 36506.
Protective Groups in Organic Chemistry, Ed. JFW McOmie, Plenum Press, 1973.
TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2003, p. 5-20, vol. 26.
The Diabetes Ready-Reference Guide for Health Care Professionals, 2000, published by the American Diabetes Association.
Von Hoersten et al., Stereological quantification of carboxyflourescein-labeled rat lung metastasis: a new method for the assessment of natural killer cell activity and tumor adhesion in vivo and in situ, J Immuno Meth, 2000, p. 25-34, vol. 239.
Demuth Hans-Ulrich
Gaertner Ulf-Torsten
Heiser Ulrich
Niestroj Andre J.
Probiodrug (AG)
Saeed Kamal A
Shterengarts Samantha L
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086333